Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Nemaura Medical Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
500
Market Cap
1.44M

Momentum Score

…

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.03
Low
1.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-1.48M
Debt / Equity
-1.70
ROE
-724.44%
Net Debt
9.93M
ROCE
124.54%
Diluted EPS TTM
-0.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -14.14M -14.24M -6.59M -4.77M -4.45M
Net income -25.10M -13.89M -6.26M -4.16M -4.45M
Selling general administrative 5.60M 6.17M 3.03M 2.77M 2.18M
Gross profit -1.48M 0.16M - - -
Reconciled depreciation 0.44M 0.23M 0.10M 0.05M 0.03M
Ebit -9.60M -7.57M -4.59M -4.78M -4.48M
Ebitda -8.17M -7.34M -4.49M -4.72M -4.44M
Depreciation and amortization 1.42M 0.23M 0.10M 0.05M 0.03M
Non operating income net other - - - 0.00M 0.02M
Operating income -9.60M -7.57M -4.59M -4.78M -4.48M
Other operating expenses 8.69M 8.07M 4.59M 4.78M 4.48M
Interest expense 6.41M 6.67M 2.01M 0.00M 0.00M
Tax provision 0.00M -0.35M -0.34M -0.61M -
Interest income - - - 0.00M 0.02M
Net interest income -6.41M -6.67M -2.01M 0.00M 0.02M
Income tax expense 10.96M -0.35M -0.34M -0.61M 0.02M
Total revenue 0.08M 0.50M 0.00M 0.00M 0.00M
Total operating expenses 7.14M 7.73M 4.59M 4.78M 4.48M
Cost of revenue 1.55M 0.34M - - -
Total other income expense net -4.55M -6.67M -2.01M 0.00M 0.02M
Net income from continuing ops -14.14M -13.89M -6.26M -4.16M -4.45M
Net income applicable to common shares -14.14M -13.89M -6.26M -4.16M -4.45M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 14.56M 22.10M 35.24M 1.22M 4.76M
Intangible assets 0.38M 1.48M 1.06M 0.21M 0.19M
Other current assets 0.36M 0.47M 1.18M 0.45M 0.74M
Total liab 26.38M 21.64M 26.88M 2.53M 2.54M
Total stockholder equity -11.81M 0.47M 8.36M -1.31M 2.23M
Deferred long term liab - - 1.28M 1.15M 1.24M
Other current liab 4.88M 1.00M 0.33M 0.08M 0.11M
Common stock 0.03M 0.02M 0.02M 0.02M 0.21M
Capital stock 0.03M 0.02M 0.02M 0.02M 0.21M
Retained earnings -51.88M -37.73M -23.84M -17.59M -13.43M
Other liab 1.02M 1.05M 1.28M 1.15M 1.24M
Cash 10.11M 17.75M 31.87M 0.11M 3.74M
Total current liabilities 22.27M 20.58M 6.42M 1.39M 1.30M
Current deferred revenue 0.12M 0.26M 0.10M 0.09M 0.07M
Net debt 9.93M 1.44M -6.94M -0.11M -3.74M
Short term debt 16.94M 19.19M 5.73M 0.92M 0.96M
Short long term debt 16.94M 19.19M 5.73M - -
Short long term debt total 20.03M 19.19M 24.92M 0.08M -
Other stockholder equity 40.99M 38.30M 32.04M 16.59M 15.47M
Property plant equipment 0.64M 0.53M 0.20M 0.16M 0.06M
Total current assets 13.54M 20.09M 33.99M 0.84M 4.52M
Net tangible assets -12.20M -1.01M 8.36M -1.53M 2.04M
Short term investments - - - - 0.00M
Net receivables 0.41M 0.38M 0.09M 0.10M 0.21M
Long term debt 3.09M - 19.19M - -
Inventory 1.75M 1.49M 0.85M 0.29M 0.04M
Accounts payable 0.33M 0.14M 0.25M 0.29M 0.16M
Accumulated other comprehensive income -0.96M -0.12M 0.14M -0.34M -0.34M
Common stock total equity - - 0.02M 0.02M 0.21M
Retained earnings total equity - - -23.84M -17.59M -13.43M
Non currrent assets other - - 0.00M 0.38M 0.25M
Non current assets total 1.03M 2.01M 1.26M 0.38M 0.25M
Long term debt total - - 19.19M - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.54M -0.96M -0.84M -0.21M 4.40M
Change to liabilities 0.19M -0.12M -0.63M 0.15M 0.82M
Total cashflows from investing activities -0.54M -0.96M -0.84M -0.21M 4.40M
Net borrowings -5.57M -12.40M 22.87M -0.04M -0.04M
Total cash from financing activities 2.08M -6.37M 37.99M 0.10M 2.05M
Change to operating activities -0.33M 0.83M -1.35M 0.20M 0.33M
Net income -14.14M -13.89M -6.26M -4.16M -4.45M
Change in cash -7.64M -14.12M 31.76M -3.63M 2.92M
Begin period cash flow 17.75M 31.87M 0.11M 3.74M 0.82M
End period cash flow 10.11M 17.75M 31.87M 0.11M 3.74M
Total cash from operating activities -8.45M -6.50M -6.00M -3.45M -3.56M
Issuance of capital stock 8.39M 3.12M 15.75M 0.15M 2.47M
Depreciation 0.44M 0.23M 0.10M 0.05M 0.03M
Other cashflows from investing activities - - -0.75M -0.05M 4.46M
Change to inventory -1.75M -0.64M -0.56M -0.26M -0.04M
Change to account receivables 0.58M -0.25M -0.68M -0.68M -2.88M
Sale purchase of stock - - 16.15M 0.18M 2.54M
Other cashflows from financing activities 3.96M 2.91M 22.84M -0.01M -0.42M
Change to netincome 5.43M 0.66M 0.11M 0.58M 0.46M
Capital expenditures 0.54M 0.96M 0.84M 0.21M 0.08M
Change receivables - - - -0.26M 0.07M
Cash flows other operating - - -0.77M 0.19M -0.46M
Cash and cash equivalents changes - - 31.15M -3.56M 2.89M
Change in working capital -2.05M -0.17M -1.96M 0.08M 0.39M
Stock based compensation 0.00M 0.22M 0.11M 0.57M 0.43M
Other non cash items 7.30M 7.11M 2.01M 0.01M 0.03M
Free cash flow -8.99M -7.46M -6.83M -3.66M -3.64M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NMRD
Nemaura Medical Inc
-
-%
0.00 - - 766.31 122.56 7183.65 -4.88
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Nemaura Medical Inc

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

57 West 57th Street, New York, NY, United States, 10019

646 416 8000

36

Name Title Year Born
Dr. Dewan Fazlul Hoque Chowdhury Ph.D. Chairman, CEO, Pres, Principal Financial Officer & Principal Accounting Officer 1973
Dr. Arash Ghadar Chief Operating Officer 1977
Mr. Bashir Timol Chief Bus. Officer & Director 1974
Mr. Jay L. Warner Head of U.S. Commercial Operations NA
Mr. Thomas Bendix Mortensen Head of E.U. Commercial Operations & Marketing NA
Ms. Samantha Sanders Global Head of Digital Programs NA
Dr. Dewan Fazlul Hoque Chowdhury Ph.D. Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…